12:00 AM
Aug 06, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Zelrix regulatory update

FDA accepted for review an NDA resubmitted by NuPathe for Zelrix to treat migraines. The agency designated the application as a...

Read the full 84 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >